Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
NCT02333188
Completed
This phase I/II trial studies the side effects of genetic analysis-guided dosing of paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRABRAX) in treating patients with gastrointestinal cancer that has spread to other parts of the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and ir... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2023
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +7 locations
Conditions: Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma, Gastric Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IV Ampulla of Vater Cancer, Stage IV Gallbladder Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer
Register for Updates
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
NCT03094884
Recruiting
Phase I study with the hypothesis that Pulsed Low Dose Radiation (PLDR) radiation delivery technique can significantly decrease the rate of severe acute esophagitis in patients receiving concurrent Chemo-radiation therapy (CRT) for non-small cell lung cancer or esophageal cancer while maintaining similar efficacy. For these patients, the rate of severe acute esophagitis during concurrent CRT is high (approximately 20%) when conventional external beam radiation is utilized. Severe acute esophagit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2023
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Esophageal Cancer
Register for Updates
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
NCT00656669
Completed
The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer. This treatment can help shrink the tumors so they can be removed to help prevent the cancer from spreading to other parts of the body. This study is being done to test the impact of adding sunitinib as a single-agent (Segment 1), followed by sunitinib plus paclitaxel (Segment 2), followed by doxorubicin and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2023
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Breast Cancer
Register for Updates
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
NCT02382406
Terminated
This is a phase I/II study for previously untreated subjects with advanced NSCLC. The study will take place in two phases. First, a cohort of twelve participants will be enrolled in phase I part and will be treated with carboplatin, nab-paclitaxel and pembrolizumab. A cohort of twelve subjects will be evaluated for safety and tolerability after 2 cycles of therapy. All subjects who receive either nab-paclitaxel or pembrolizumab will be evaluable. If 33% of subjects or less have unacceptable toxi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2023
Locations: City of Hope, Duarte, California +4 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712
Terminated
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2023
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +797 locations
Conditions: Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
Register for Updates
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
NCT03588039
Terminated
This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/18/2023
Locations: Mayo Clinic, Phoenix, Arizona +3 locations
Conditions: Solid Tumor
Register for Updates
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
NCT03544567
Completed
This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/18/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +9 locations
Conditions: Angiosarcoma of Skin
Register for Updates
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
NCT01367002
Completed
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine Serous Papillary Carcinoma (USPC) patients overexpressing Her2/neu at 3+ level by immunohistochemistry (IHC)or positive by fluorescence in situ hybridization (FISH).
Gender:
FEMALE
Ages:
All
Trial Updated:
05/15/2023
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +19 locations
Conditions: Endometrial Cancer
Register for Updates
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
NCT05251038
Withdrawn
This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2023
Locations: Northwestern University, Chicago, Illinois
Conditions: Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
Register for Updates
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
NCT03126435
Completed
The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2023
Locations: Compassionate Cancer Care Medical Group, Inc, Corona, California +67 locations
Conditions: Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
Register for Updates
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01912625
Terminated
This phase I trial studies the side effects and the best dose of trametinib when given together with combination chemotherapy and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota +4 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
NCT03579771
Active Not Recruiting
This phase II trial studies how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma). Drugs used in chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy before surgery may make the... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/03/2023
Locations: Emory University Hospital Midtown, Atlanta, Georgia +6 locations
Conditions: Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Register for Updates